Loading organizations...
Genascence is a clinical-stage biotechnology company developing gene therapies for musculoskeletal diseases, with a primary focus on osteoarthritis. The organization's lead product, GNSC-001, is a one-time intra-articular injection utilizing a recombinant adeno-associated virus vector to deliver an interleukin-1 receptor antagonist. This therapy enables sustained production of the antagonist within joint cells to inhibit inflammation and cartilage breakdown for conditions affecting millions of patients. The US Food and Drug Administration recently granted both Fast Track and Regenerative Medicine Advanced Therapy designations to the treatment, which is scheduled to enter a Phase IIb/III clinical study in 2026. The company's core technology was originally licensed from institutional partners including the Mayo Clinic and the University of Florida, with further scientific development led by Annahita Keravala and Paul Robbins. Genascence was officially founded in the year 2017 by Tom Chalberg.
Genascence has raised $16.0M across 2 funding rounds.
Genascence has raised $16.0M in total across 2 funding rounds.
Genascence has raised $16.0M in total across 2 funding rounds.
Genascence's investors include Pacira BioSciences, DeepWork Capital, Polymerase Capital, Jackson Streeter.
Genascence has raised $16.0M across 2 funding rounds. Most recently, it raised $5.0M Series A in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2022 | $5M Series A | Pacira BioSciences | DeepWork Capital, Polymerase Capital, Jackson Streeter | Announced |
| Jan 1, 2022 | $11M Series A | — | DeepWork Capital | Announced |
Genascence is a clinical-stage biotechnology company developing gene therapies for prevalent musculoskeletal diseases, primarily osteoarthritis (OA), a leading cause of disability, chronic pain, and opioid addiction risk.[1][2][5] Its lead product, GNSC-001, targets knee OA via a single-dose intra-articular gene therapy, with a Phase 1b clinical trial initiated in early 2024 and actively recruiting at 10 U.S. sites, expecting initial six-month data in Q4 2024.[1][3] The company serves millions affected by these conditions, addressing unmet needs in durable, non-opioid treatments, and has raised $10.5M in funding while operating from Palo Alto, California, with under 25 employees and revenue below $5M.[1]
Genascence was founded in 2017 by Thomas W. Chalberg, PhD, MBA (Chairman & CEO) and Annahita Keravala, PhD (Chief Scientific Officer), both with deep expertise in gene therapy and biotech entrepreneurship.[1][4][5] Chalberg, a Silicon Valley scientist-entrepreneur, previously founded and led SightGlass Vision to acquisition by CooperVision and EssilorLuxottica in 2021; Keravala brings over 20 years in gene therapy, including 12+ years in industry roles advancing vectors for ophthalmic, cardiac, neurological, and musculoskeletal applications at firms like CODA Biotherapeutics.[4] The idea emerged from their vision to extend gene therapy beyond rare diseases to high-prevalence conditions like OA, leveraging novel vector technologies; early traction includes advancing GNSC-001 to clinical stages.[1][3][4][5]
Genascence rides the gene therapy expansion from rare diseases to prevalent conditions like OA, fueled by advances in AAV vectors and intra-articular delivery amid a musculoskeletal crisis—OA impacts over 500 million globally, driving disability and healthcare costs.[1][5] Timing aligns with post-2020 regulatory successes (e.g., FDA approvals for gene therapies) and investor interest in non-opioid pain solutions amid the addiction epidemic.[1] Market forces favoring it include aging populations, rising OA incidence, and biotech funding for platform technologies; by targeting high-prevalence diseases, Genascence influences the ecosystem, potentially lowering barriers for gene therapy scalability and inspiring similar pivots in orthopedics.[2][3][5]
Genascence is poised for Phase 1b readouts in late 2024, potentially validating GNSC-001 and unlocking further funding or partnerships in a booming gene therapy market.[1] Trends like improved vectors, combo therapies with biologics, and AI-driven trial design will accelerate its path to Phase 2/3 and commercialization, especially if data shows durable efficacy. Its influence could grow by proving gene therapy's viability for everyday diseases, reshaping musculoskeletal care and amplifying biotech's role in chronic pain. This positions Genascence as a renaissance leader in extending gene therapy's reach.[5]
